Janssen Biotech, Inc.

Human Genome Sciences, Inc.

Marc Chevrier

Jarrat Jordan

Newman Yeilding

Kamyar Farahi

Jessica Schreiter

Melissa D Perkins

Matteo Cesaroni

Daniel J Odenheimer

William W Freimuth

Zhenshao Zhong

William Freimuth

Daniel Odenheimer

Methods for administration of an anti-IFN-α/-ω antibody by subcutaneous or intravenous administration in a clinically proven safe amount are provided. Also provided are methods for clinically proven safe treatment of IFN-I mediated diseases, such as systemic lupus erythematosus (SLE), by subcutaneous or intravenous administration of an anti-IFN-α/-ω antibody.

Method of administration of an anti-IFN-α/-ω antibody

Type I interferon (IFN-I) signatures are useful in methods of diagnosing whether a subject (or patient) with IFN-I mediated disease will be responsive to treatment with an IFN-I inhibitor and treating or refraining from treating the subjects.

Type I interferon signatures and methods of use

A method of treating an IL-12/23-related disease in a patient using an increasing dosing interval, comprises increasing the dosing interval of IL-12/IL-23 antibody to a patient, wherein the antibody is administered initially and after 4 weeks, after 16 weeks and after 28 weeks, and increasing the dosing interval after 28 weeks to an increased interval, e.g., every 16, 20 or 24 weeks.

Method of treating psoriatic arthritis with increased interval dosing of anti-IL12/23 antibody

Method of treating psoriasis with increased interval dosing of anti-IL12/23 antibody

The present invention relates to methods and compositions for use in treatment of patients with autoantibody positive disease. In a specific embodiment, the present invention relates to a method of treating a patient that has an ANA titer of 1:80 or greater and/or greater than or equal to 30 IU/ml of anti-dsDNA antibodies in his/her blood plasma or serum comprising administering a therapeutically effective amount of an immunomodulatory agent, such as an antagonist of Neutrokine-alpha. Additionally provided is a method of reducing the frequency and/or quantity of corticosteroid administration to patients. In preferred embodiments, the patient has systemic lupus erythematosus. Methods for determining if a lupus patient is responding to medical treatment are also provided.

Methods and compositions for use in treatment of patients with autoantibody positive disease

Growing community of inventors

Collegeville, PA, United States of America

Marc Chevrier